Brief: Transgene And Bioinvent Receive IND Approval From FDA For BT-001

BioInvent International AB

27/05/2021 07:33

May 27 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE AND BIOINVENT RECEIVE IND APPROVAL FROM THE U.S.
FDA
FOR BT-001, A NOVEL ONCOLYTIC VIRUS FOR THE TREATMENT OF SOLID
TUMORS
    * THIS IND WILL ALLOW PATIENTS IN U.S. TO BE ENROLLED INTO
ONGOING
PHASE I/IIA CLINICAL TRIAL OF THIS NOVEL ONCOLYTIC VIRUS BT-001

Source text for Eikon:  ID:nBw3bSFGCa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))